New Delhi, India — Following the tragic deaths of 20 children linked to tainted cough syrup, the Central Drugs Standard Control Organisation (CDSCO) has ordered drug regulators nationwide to enhance testing and monitoring protocols for pharmaceuticals prior to market release.
The fatalities occurred in Chhindwara, where children being treated for kidney failure were found to have ingested the contaminated Coldrif syrup. The CDSCO emphasized the critical need for rigorous testing of all raw materials used in drug production, including excipients, before they are incorporated into formulations. This directive aligns with existing regulatory standards that mandate rigorous testing of every batch of raw materials and finished products in approved laboratories.
In response to the crisis, the Tamil Nadu government swiftly acted to seal the manufacturing facility responsible for the problematic syrup. A special investigation team from Madhya Pradesh has also traveled to Chennai to examine the company’s registered office and its plant in Kancheepuram as part of a broader investigation into the circumstances surrounding the children’s deaths.
Tamil Nadu’s Health Minister, Ma Subramanian, confirmed that the syrup contained 48.6 percent of a hazardous substance. Initial assessments indicated that samples collected by officials were adulterated, prompting the state to issue a stop production order. If the manufacturer cannot provide sufficient justification for its operations, it could face shutdown. The government is currently awaiting the company’s explanation to determine the next legal steps.
The manufacturer, which has been in operation for 14 years, was licensed to produce the syrup at its facility in Sunguvarchatram. Following the discovery of diethylene glycol in the syrup, state officials issued a second notice threatening criminal proceedings against the company. Production was halted immediately after the adulteration was confirmed.
As a precautionary measure, the sale of Coldrif has been banned not only in Tamil Nadu but also in Kerala and Madhya Pradesh. Advisories have been disseminated in Puducherry and Odisha to prevent the syrup from being sold in those regions.
The CDSCO’s directive highlights the need for drug controllers to implement stringent vendor qualification processes, ensuring that manufacturers procure raw materials solely from approved suppliers. Recommendations for oversight measures include regular inspections, distribution of informative circulars, and urging manufacturers to prioritize safety and quality, all aimed at preventing future incidents.
On October 4, the Tamil Nadu Food Safety and Drug Administration confirmed the presence of adulterants in samples inspected from the Kancheepuram facility, leading to an immediate halt of all production. Authorities have cautioned that criminal action may ensue based on findings from ongoing investigations.
This incident has raised serious concerns about pharmaceutical safety standards in India, underlining the ongoing need for vigilance and compliance in the manufacturing and regulation of medical products. Consumer confidence hangs in the balance as the authorities work to ensure similar tragedies are avoided in the future.